A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
NCT ID: NCT00111644
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
302 participants
INTERVENTIONAL
2005-03-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
beta-lactam
750mg iv q 23h for 3-14 days
2
beta-lactam
1500mg iv q 12h for 3-14 days
3
Ceftriaxone
1000mg iv daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftriaxone
1000mg iv daily
beta-lactam
750mg iv q 23h for 3-14 days
beta-lactam
1500mg iv q 12h for 3-14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason;
* fever;
* new or increased productive cough;
* chest pain, shortness of breath, or rapid breathing.
Exclusion Criteria
* nursing home or extended care within 60 days before study;
* concomitant bacterial infection requiring antibiotics;
* long-term immunosuppressive therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Detroit, Michigan, United States
Butte, Montana, United States
Holmdel, New Jersey, United States
Winston-Salem, North Carolina, United States
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Ciudadela, , Argentina
Córdoba, , Argentina
Córdoba, , Argentina
Granadero Baigorria, , Argentina
Paraná, , Argentina
Rosario, , Argentina
Rousse, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Santiago, , Chile
Valdivia, , Chile
Zagreb, , Croatia
Budapest, , Hungary
Nyíregyháza, , Hungary
Törökbálint, , Hungary
Zalaegerszeg, , Hungary
Daugavpils, , Latvia
Riga, , Latvia
Riga, , Latvia
Kaunas, , Lithuania
Klaipėda, , Lithuania
Vilnius, , Lithuania
Lima, , Peru
Lima, , Peru
Lima, , Peru
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Constanța, , Romania
Craiova, , Romania
Banská Bystrica, , Slovakia
Nitra, , Slovakia
Nitra, , Slovakia
Poprad, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WI18273
Identifier Type: -
Identifier Source: org_study_id